Wisconsin is currently home to 1287 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
Recruiting
This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a sp... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
02/11/2025
Locations: Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin
Conditions: Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma
Recruiting
This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes. These outcomes include radiographic measures such as fracture healing, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: SSM Health St. Mary's Hospital, Madison, Wisconsin
Conditions: Fractures, Bone
Lung Ultrasound - Prospective Study
Recruiting
The goal of this clinical trial is to determine whether lung ultrasound can predict extubation success in neonates with respiratory distress. Participants will undergo a lung ultrasound pre- and post-extubation.
Gender:
ALL
Ages:
6 months and below
Trial Updated:
02/11/2025
Locations: Unity-Point Health Meriter, Madison, Wisconsin
Conditions: Respiratory Distress of Newborn
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Recruiting
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Ductal Adenocarcinoma
Enhancing Diabetes Management Approaches for Black and Hispanic Patients With Uncontrolled Diabetes
Recruiting
The purpose of the study is to learn about the best way to enhance pharmacy-related care for diabetes self-management. This research is being done because we want to improve use of medicines and diabetes management among Black and Hispanic adults with type 2 diabetes and find out which of type of support may improve diabetes self-management for Black and Hispanic adults. Participants will be assigned to one of 4 groups, and will either: * receive care as usual; or, * receive added medicine ma... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/11/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Diabetes, Diabetes Type 2
Everolimus Aging Study
Recruiting
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/11/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Aging, Insulin Resistance
Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906
Recruiting
Main study: Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GAL1906 for the correction of wrinkles in the décolletage area. Sub-study: To evaluate imaging interpretation of mammograms in subjects who were enrolled and treated in the 43USRV1906 main study. The sub-study will determine if hyaluronic acid injections in the décolletage interfere with diagnosis or interpretation of mammogram results.
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
02/11/2025
Locations: Galderma Research Site, Mequon, Wisconsin
Conditions: Wrinkle
AB-1002 in Patients With Class III Heart Failure
Recruiting
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. Patients with non-ischemic cardiomyopathy will be enrolled until up to 17 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Wisconsin at Madison, Madison, Wisconsin
Conditions: Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure,Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Recruiting
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Aurora St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Septic Shock, Endotoxemia
Characterization of Fetal Lung With Quantitative Ultrasound
Recruiting
The purpose of the study is to show if it's possible to use a special kind of ultrasound called backscatter quantitative ultrasound (bQUS) to check on a baby's lungs when the mother is 36 weeks pregnant. 12 participants will be on study for a single 30 minute ultrasound between 32 and 36 weeks of pregnancy.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
02/10/2025
Locations: Meriter Hospital, Madison, Wisconsin
Conditions: Respiratory Complication, Fetal Lung Imaging
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Recruiting
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
02/10/2025
Locations: Gundersen Health System, La Crosse, Wisconsin
Conditions: Retinitis Pigmentosa
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
02/10/2025
Locations: Research Site, Madison, Wisconsin
Conditions: Breast Cancer, Early Breast Cancer